Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: A case report of a patient on long-term follow-up

Internal Medicine

Volumn 44, Issue 9, 2005, Pages 958-962

  Tohyama, Tatsuhiko ^a   Matsui, Kazuhiro ^b   Kitagawa, Kiyohide ^c  

^a Kohryo Clinic   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Takaoka Kohseiren Hospital   (Japan)

Author keywords

Carcinoid heart disease; Carcinoid syndrome; Carcinoid tumor; Octreotide acetate; Primary hepatic; Primary hepatic carcinoid tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OCTREOTIDE;

ADULT; ARTICLE; ASCITES; AUTOPSY; CARCINOID SYNDROME; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CARCINOMA; LONGITUDINAL STUDY; MEDICAL EXAMINATION; METASTASIS; MULTIPLE ORGAN FAILURE; SYMPTOMATOLOGY;

ANTINEOPLASTIC AGENTS, HORMONAL; ASCITES; CARCINOID HEART DISEASE; CARCINOID TUMOR; FEMALE; HUMANS; LIVER NEOPLASMS; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; OCTREOTIDE; TIME FACTORS;

EID: 27844505664     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.958     Document Type: Article

References (13)

1. Sano K, Kosuge T, Yamamoto J, et al. Primary hepatic carcinoid tumors confirmed with long-term follow-up after resection. Hepatogastroenterology 46: 2547-2550, 1999.
2. Tornebrandt K, Eskilsson J, Nobin A. Heart involvement in metastatic carcinoid disease. Clin Cardiol 9: 13-19, 1986.
3. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med 348: 1005-1015, 2003.
4. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation 87: 1188-1196, 1993.
5. Mehta DC, Warner RR, Parnes I, Weiss M. An 18-year follow-up of primary hepatic carcinoid with carcinoid syndrome. J Clin Gastrenterol 23: 60-62, 1996.
6. Ahlman H, Westberg G, Wängberg B, et al. Treatment of liver metastases of carcinoid tumors. World J Surg 20: 196-202, 1996.
7. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long acting somatostatin analogue. N Engl J Med 315: 663-666, 1986.
8. Deguchi H, Deguchi K, Tsukada T, et al. Long-term survival in a patient with malignant carcinoid treated with high-dose OA. Intern Med 33: 100-102, 1994.
9. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934-944, 1998.
10. Godwin JD II. Carcinoid tumors. An analysis of 2,837 cases. Cancer 36: 560-569, 1975.
11. Lips CJ, Lentjes EG, Höppener JW. The spectrum of carcinoid tumours and carcinoid syndrome. Ann Clin Biochem 40: 612-627, 2003.
12. Zuetenhorst JM, Bonfrer JM, Korse CM, Bakkec R, van Tinteren H, Taal BG. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-β and fibroblast growth factor. Cancer 97: 1609-1615, 2003.
13. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232, 1991.